[1] 杨崇礼,张晓波.全国再生障碍性贫血发病情况调查[J].中国医学科学院学报,1992,14(1):6-11.
[2] DUFOUR C, PILLON M, SOCIÈ G, et al. Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. Br J Haematol. 2015;169(4):565-573.
[3] DUFOUR C, PILLON M, PASSWEG J, et al. Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2014;99(10):1574-1581.
[4] EBENS CL, DEFOR TE, TRYON R, et al. Comparable Outcomes after HLA-Matched Sibling and Alternative Donor Hematopoietic Cell Transplantation for Children with Fanconi Anemia and Severe Aplastic Anemia. Biol Blood Marrow Transplant. 2018;24(4):765-771.
[5] YOSHIDA N, KOBAYASHI R, YABE H, et al. First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapy. Haematologica. 2014;99(12):1784-1791.
[6] GALLO S, WOOLFREY AE, BURROUGHS LM, et al. Marrow grafts from HLA-identical siblings for severe aplastic anemia: does limiting the number of transplanted marrow cells reduce the risk of chronic GvHD? Bone Marrow Transplant. 2016;51(12):1573-1578.
[7] 付蓉.再生障碍性贫血诊断与治疗中国专家共识(2017年版)[J].中华血液学杂志,2017,38(1):1-5.
[8] KILLICK SB, BOWN N, CAVENAGH J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187-207.
[9] GUPTA V, EAPEN M, BRAZAUSKAS R, et al. Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. Haematologica. 2010; 95(12):2119-2125.
[10] PASSWEG JR, MARSH JC. Aplastic anemia: first-line treatment by immunosuppression and sibling marrow transplantation. Hematology Am Soc Hematol Educ Program. 2010;2010:36-42.
[11] GIAMMARCO S, PEFFAULT DE LATOUR R, SICA S, et al. Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved? Blood. 2018;131(17):1989-1992.
[12] SHIN SH, JEON YW, YOON JH, et al. Comparable outcomes between younger (⩽40 years) and older (>40 years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplantation using fludarabine-based conditioning. Bone Marrow Transplant. 2016; 51(11):1456-1463.
[13] RICE C, EIKEMA DJ, MARSH JCW, et al. Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia. Biol Blood Marrow Transplant. 2019;25(3):488-495.
[14] SCHREZENMEIER H, PASSWEG JR, MARSH JC, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood. 2007; 110(4):1397-1400.
[15] BACIGALUPO A, SOCIÉ G, SCHREZENMEIER H, et al. Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. Haematologica. 2012;97(8):1142-1148.
[16] BACIGALUPO A, SOCIÉ G, HAMLADJI RM, et al. Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis. Haematologica. 2015;100(5): 696-702.
[17] STORB R, ETZIONI R, ANASETTI C, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 1994; 84(3):941-949.
[18] KAHL C, LEISENRING W, DEEG HJ, et al. Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. Br J Haematol. 2005;130(5):747-751.
[19] BACIGALUPO A. How I treat acquired aplastic anemia. Blood. 2017; 129(11):1428-1436.
[20] CHAUDHRY QUN, IFTIKHAR R, SATTI TM, et al. Outcome of Fludarabine-Based Conditioning in High-Risk Aplastic Anemia Patients Undergoing Matched Related Donor Transplantation: A Single-Center Study from Pakistan. Biol Blood Marrow Transplant. 2019;25(12): 2375-2382.
[21] DUFOUR C, VEYS P, CARRARO E, et al. Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT. Br J Haematol. 2015; 171(4):585-594.
[22] CHOI YB, YI ES, LEE JW, et al. Immunosuppressive therapy versus alternative donor hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an HLA-matched familial donor. Bone Marrow Transplant. 2017;52(1):47-52.
[23] DARRIGO LG JR, COLTURATO V, DE SOUZA MP, et al. Allogeneic Bone Marrow Transplants for Pediatric Severe Aplastic Anemia: Real-world Data comparing Matched Related and Unrelated Donors in a Developing Country. Retrospective study on behalf of the Pediatric Hematopoietic Stem Cell Transplant Working Group of the Brazilian Bone Marrow Transplantation Society (SBTMO) and the Brazil-Seattle Consortium (Gedeco). Pediatr Transplant. 2019;23(7):e13552.
[24] VAHT K, GÖRANSSON M, CARLSON K, et al. High Graft-versus-Host Disease-Free, Relapse/Rejection-Free Survival and Similar Outcome of Related and Unrelated Allogeneic Stem Cell Transplantation for Aplastic Anemia: A Nationwide Swedish Cohort Study. Biol Blood Marrow Transplant. 2019;25(10):1970-1974.
[25] 王玲,王恒湘,朱玲.HLA相合无关供者造血干细胞移植联合脐带间充质干细胞输注治疗儿童重型再生障碍性贫血19例疗效及安全性研究[J].中华血液学杂志,2016,37(6):453-457.
[26] ANDERLINI P, WU J, GERSTEN I, et al. Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study. Lancet Haematol. 2015;2(9):e367-375.
[27] HAMAD N, DEL BEL R, MESSNER HA, et al. Outcomes of hematopoietic cell transplantation in adult patients with acquired aplastic anemia using intermediate-dose alemtuzumab-based conditioning. Biol Blood Marrow Transplant. 2014;20(11):1722-1728.
[28] MARSH JC, PEARCE RM, KOH MB, et al. Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014;49(1):42-48.
[29] XU ZL, ZHOU M, JIA JS, et al. Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia. Bone Marrow Transplant. 2019;54(8):1319-1326.
[30] YANG S, YUAN X, MA R, et al. Comparison of Outcomes of Frontline Immunosuppressive Therapy and Frontline Haploidentical Hematopoietic Stem Cell Transplantation for Children with Severe Aplastic Anemia Who Lack an HLA-Matched Sibling Donor. Biol Blood Marrow Transplant. 2019;25(5):975-980.
[31] 唐湘凤,井远方,卢伟.单倍型造血干细胞移植治疗儿童获得性重型再生障碍性贫血的临床研究[J].中华血液学杂志, 2019,40(4):301-305.
[32] XU LP, JIN S, WANG SQ, et al. Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant. J Hematol Oncol. 2017;10(1):25.
[33] KIM H, IM HJ, KOH KN, et al. Comparable Outcome with a Faster Engraftment of Optimized Haploidentical Hematopoietic Stem Cell Transplantation Compared with Transplantations from Other Donor Types in Pediatric Acquired Aplastic Anemia. Biol Blood Marrow Transplant. 2019;25(5):965-974.
[34] XU LP, WANG SQ, WU DP, et al. Haplo-identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study. Br J Haematol. 2016;175(2):265-274.
[35] 许兰平,左扬杨.《Upfront haploidentical transplant for acquired severe aplastic anemia:registry-based comparison with matched related transplant》解读[J].临床血液学杂志, 2017,30(6):834-838.
[36] WANG Z, YU H, CAO F, et al. Donor-derived marrow mesenchymal stromal cell co-transplantation following a haploidentical hematopoietic stem cell transplantation trail to treat severe aplastic anemia in children. Ann Hematol. 2019;98(2):473-479.
[37] LIU Z, ZHANG Y, XIAO H, et al. Cotransplantation of bone marrow-derived mesenchymal stem cells in haploidentical hematopoietic stem cell transplantation in patients with severe aplastic anemia: an interim summary for a multicenter phase II trial results. Bone Marrow Transplant. 2017;52(5):704-710.
[38] XU L, LIU Z, WU Y, et al. Clinical evaluation of haploidentical hematopoietic combined with human umbilical cord-derived mesenchymal stem cells in severe aplastic anemia. Eur J Med Res. 2018;23(1):12.
[39] YUE C, DING Y, GAO Y, et al. Cotransplantation of haploidentical hematopoietic stem cells and allogeneic bone marrow-derived mesenchymal stromal cells as a first-line treatment in very severe aplastic anemia patients with refractory infections. Eur J Haematol. 2018;100(6):624-629.
[40] DEZERN AE, ZAHURAK M, SYMONS H, et al. Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia. Biol Blood Marrow Transplant. 2017;23(3):498-504.
[41] XU L, FU B, WANG W, et al. Haploidentical hematopoietic cell transplantation for severe acquired aplastic anemia: a case-control study of post-transplant cyclophosphamide included regimen vs. anti-thymocyte globulin & colony-stimulating factor-based regimen. Sci China Life Sci. 2019 Aug 14. doi: 10.1007/s11427-019-9585-x. [Epub ahead of print]
[42] PAGLIUCA S, PEFFAULT DE LATOUR R, VOLT F, et al. Long-Term Outcomes of Cord Blood Transplantation from an HLA-Identical Sibling for Patients with Bone Marrow Failure Syndromes: A Report From Eurocord, Cord Blood Committee and Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017;23(11):1939-1948.
[43] KUWATSUKA Y, KANDA J, YAMAZAKI H, et al. A Comparison of Outcomes for Cord Blood Transplantation and Unrelated Bone Marrow Transplantation in Adult Aplastic Anemia. Biol Blood Marrow Transplant. 2016;22(10):1836-1843.
[44] ONISHI Y, MORI T, KAKO S, et al. Outcome of Second Transplantation Using Umbilical Cord Blood for Graft Failure after Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia. Biol Blood Marrow Transplant. 2017;23(12):2137-2142.
[45] HOUGH R, DANBY R, RUSSELL N, et al. Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols. Br J Haematol. 2016;172(3):360-370.
[46] LAMERS CH, WIJERS R, VAN BERGEN CA, et al. CD4+ T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantation. Blood. 2016;128(17):2165-2174.
[47] STIFF PJ, MONTESINOS P, PELED T, et al. Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation. Biol Blood Marrow Transplant. 2018; 24(7):1463-1470.
[48] YAMAMOTO H, KATO D, UCHIDA N, et al. Successful sustained engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with severe aplastic anemia. Blood. 2011;117(11):3240-3242.
[49] PEFFAULT DE LATOUR R, CHEVRET S, JUBERT C, et al. Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study. Blood. 2018;132(7): 750-754.
[50] KUDO K, MURAMATSU H, NARITA A, et al. Unrelated cord blood transplantation in aplastic anemia: is anti-thymocyte globulin indispensable for conditioning? Bone Marrow Transplant. 2017;52(12): 1659-1661.
[51] SARVARIA A, BASAR R, MEHTA RS, et al. IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. Blood. 2016;128(10):1346-1361.
[52] GEORGIA A, CHRISTINA O, AIKATERINI K, et al. Successful long-term hematological and immunological reconstitution by autologous cord blood transplantation combined with post-transplant immunosuppression in two children with severe aplastic anemia. Pediatr Transplant. 2019;23(1):e13320.
[53] SUN Y, LIU Z, XIAO J, et al. Autologous cord blood transplantation in children with acquired severe aplastic anemia. Pediatr Transplant. 2019;23(1):e13325.
[54] 杨世伟,马荣军,赵娟娟,等.不同方式异基因造血干细胞移植一线治疗儿童及青少年重型再生障碍性贫血的比较[J].中华血液学杂志,2018,39(3): 184-189.
[55] GEORGES GE, DONEY K, STORB R. Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment. Blood Adv. 2018;2(15):2020-2028.
|